CPRX Stock Discussion
Catalyst Pharmaceutical Partners, Inc. Description
Catalyst Pharmaceutical Partners, Inc. operates as development-stage specialty pharmaceutical company. It focuses on the development and commercialization of novel prescription drugs targeting rare (orphan) neuromuscular and neurological diseases and disorders. The company's principal product includes Firdapse that is in Phase III clinical trial for the treatment of Lambert-Eaton Myasthenic Syndrome. It also develops CPP-115, a GABA aminotransferase inhibitor for the treatment of epilepsy and other selected central nervous disease indications; and CPP-109 for the treatment of Tourette Syndrome. Catalyst Pharmaceutical Partners, Inc. has strategic collaboration agreement with BioMarin. The company was founded in 2002 and is based in Coral Gables, Florida.
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Pharmaceutical Health Sciences Medication Virotherapy Disorders Epilepsy Pharmaceutical Sciences Prescription Drugs Stage Specialty Pharmaceutical Myasthenia Pharmaceutical Partners Treatment Of Epilepsy Lambert Eaton Myasthenic Lambert Eaton Myasthenic Syndrome Tourette Syndrome Treatment Of Tourette Syndrome Urological Diseases
Recent Comments
- TraderMike on Bollinger Band Squeeze
- TraderMike on Bollinger Band Squeeze
- OpenCat584 on Bollinger Band Squeeze
- Dr_Duru on Expansion Breakout
- TraderMike on New Scans: Strong, Oversold Stocks and Weak, Overbought Stocks
From the Blog
Featured Articles